Participated · Series A · Jul 2026

Founded in 2021 and based in Munich, Project Q builds automated systems that process and analyze intelligence data and provide decision-support tools for defence and security users. Its core product set centers on AI-powered software and bespoke AI models for defence applications. Following rapid earlier fundraising activity, the company has just closed a €15 million Series A led by Expeditions with participation from Hensoldt and Heliad. Project Q intends to use the new capital to expand its software capabilities and further develop defence-specific AI models. Company leadership has emphasized the goal of enabling European defence organizations to maintain sovereign control over their digital infrastructure. The articles do not report revenue, user counts, or other operating metrics.

Participated · Seed · Jun 2026

Bayshore offers a platform that turns regulations, policies, and other rulesets into machine-readable code to create deterministic, auditable guardrails for AI agents and compliance workflows. Its system acts as a central entry point for legal and compliance requests, enabling automated handling of low-risk cases and escalation of complex matters to human experts while maintaining consistency across jurisdictions and programs. The platform emphasizes auditability to reduce legal risk and ensure compliance teams can rely on AI-driven processes. Multiple Global 2000 companies are already deploying Bayshore’s solution. The company plans to use the new seed funding to advance the product, expand its team, and deliver custom deployments for highly regulated customers. Bayshore is hiring across AI engineering, legal engineering, and go-to-market roles.

Participated · Seed · Jun 2026

encosa offers a complete batteries storage solution for mid-sized companies, handling selection, installation, commissioning and ongoing operation while combining hardware, financing options (purchase, rental or lease) and a proprietary AI-supported software platform. Its platform integrates behind-the-meter cost savings and front-of-the-meter market participation to optimize economic operation. Typical customers are energy-intensive industries such as chemical, glass and machinery, and encosa reports that solutions typically pay back within 18 months to five years. Customers receive immediate lower energy costs, additional revenue from feed-in, CO2 reductions and ESG reporting benefits. The company was founded in 2024 and is headquartered in Munich, and the team includes Sebastian Becker and Sascha Koberstaedt.

Led · Seed · Jan 2026

GeneralMind is a Berlin-based AI startup founded in 2025 by the team behind German unicorn Razor Group. The company is developing an autonomous AI platform—described as a “System of Action”—that executes end-to-end, repetitive white-collar workflows across commonly used enterprise tools such as email, spreadsheets and ERP software. Its flagship feature, AI Autopilot, functions as a human-supervised assistant that parses unstructured communications and completes routine tasks without manual intervention. The technology is aimed at large enterprises; early customers already include firms listed on the NASDAQ, MDAX and SDAX indices. With a secondary office in Bangalore, the startup intends to leverage a distributed team for engineering and go-to-market execution. Fresh capital will be used to accelerate product development, scale operations and broaden adoption throughout Europe and additional regions. No revenue, user or other operating metrics were disclosed in the articles reviewed.

Participated · Equity · Oct 2025

StratifAI is a precision oncology company founded in Berlin that applies artificial intelligence to identify prognostic and predictive biomarkers from multimodal clinical data. Its core product, the Polaris™ platform, fuses H&E histology with RNA-Seq gene expression to link spatial tumor signals directly to patient outcomes, speeding up biomarker discovery while lowering associated costs. The company is assembling a large multimodal reference dataset from collected tumor samples to continually expand its portfolio of spatial biomarkers. StratifAI’s first commercial test, Polaris™ Breast, assesses metastasis risk in early breast cancer and is currently undergoing regulatory review in the EU and the United States. Fresh capital is earmarked to complete clinical validation of Polaris™ Breast and to establish a scalable regulatory framework for clinical AI diagnostics. In parallel, the firm is deepening collaborations with oncology centers and pharmaceutical partners to build the clinical evidence required for guideline inclusion and routine practice. By leveraging growing digital pathology data, StratifAI aims to unlock a sizable, under-served market in cancer diagnostics and deliver more individualized and equitable care for patients with solid tumors.